La importancia de la primera línea en el cáncer de cabeza y cuello resistente o metastásico

22 / 43

22
IDR durante el mantenimiento con CTX:
estudios EXTREME1 and DIRECT2
• 1. Vermorken JB, et al. N Engl J Med 2008;359:1116–27
• 2. Guigay J, et al. ESMO 2016 (Abstract 967P)
EXTREME
• Cutaneous toxicities were observed in 20/219 (9.1%) of EXTREME study patients (safety population; grade ≥3)1
• and 25/72 (34.7%) of DIRECT study patients (maintenance phase; all grades)2
• Neutropenia was the most common non-cutaneous toxicity observed in both the EXTREME and DIRECT study patients1,2
0
20
40
60
80
100
Cetuximab maintenance
therapy (N=100)
Patients (%) with cetuximab RDI
≥80%
82%
DIRECT
0
20
40
60
80
100
Cetuximab maintenance
therapy (N=72)
Patients (%) with cetuximab RDI
≥80%
79%